drugset / Trial / NCT05161637
Phase 2/3 Study of TLC590 for Postsurgical Pain Management
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2/3 randomized, double-blind, 2-part, comparator- and placebo-controlled study to assess the safety, pharmacokinetics and efficacy of postsurgical local infiltration in adult subjects following inguinal hernia repair surgery.
Timeline
- Start
- 2025-04
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupivacaine | Other / unclassified | 75 mg | Other |
| Comparator | Ropivacaine | Other / unclassified | 150 mg | Other |
| Subject | TLC590 | Unknown | 490 mg | Other |
| Subject | TLC590 | Unknown | 588 mg | Other |
Indications
No indication recorded.